CD8A and neoplasm: V-9302, a glutamine transporter inhibitor targeting SLC1A5/ASCT2, has validated the effect of attenuating tumor cell proliferation and increasing the infiltration of CD8+T cells (Schulte et al., 2018; Pallett et al., 2021).